Standard BioTools Inc. Other Accrued Liabilities, Current
Standard BioTools Inc. (LAB) had Other Accrued Liabilities, Current of $2.16 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Other Accrued Liabilities, Current $2.16M.
- 2026-03-31: Other Accrued Liabilities, Current $1.53M.
- 2025-12-31: Other Accrued Liabilities, Current $1.45M; Other Accrued Liabilities, Current as first filed $3.58M.
- 2025-09-30: Other Accrued Liabilities, Current $2.50M.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.16M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.53M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.45M 10-Q · filed 2026-08-05 | $3.58M 10-K · filed 2026-03-16 |
| 2025-09-30 | $2.50M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.14M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $4.65M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $4.66M 10-K · filed 2026-03-16 | $6.90M 10-K · filed 2025-03-11 |
| 2024-09-30 | $7.26M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $6.97M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $5.94M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $4.03M 10-K · filed 2025-03-11 | $1.10M 10-K · filed 2024-03-01 |
| 2023-09-30 | $714.00K 10-Q · filed 2023-11-07 | |
| 2022-12-31 | $913.00K 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |